Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minoru Fukuda

Showing results (251-260 of 254) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 254 results.
Cancer Medicine|May 13, 2021
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatmentNaoko Sueoka-Aragane, Chiho Nakashima, Hironori Yoshida, et al.
Journal of Clinical Medicine|June 11, 2020
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous TreatmentAkira Nakao, Osamu Hiranuma, Junji Uchino, et al.
The Oncologist|January 18, 2019
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II TrialAkira Nakao, Osamu Hiranuma, Junji Uchino, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancerKazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, et al.
Pageof 26

Showing results (251-260 of 254) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 254 results.
Cancer Medicine|May 13, 2021
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatmentNaoko Sueoka-Aragane, Chiho Nakashima, Hironori Yoshida, et al.
Journal of Clinical Medicine|June 11, 2020
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous TreatmentAkira Nakao, Osamu Hiranuma, Junji Uchino, et al.
The Oncologist|January 18, 2019
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II TrialAkira Nakao, Osamu Hiranuma, Junji Uchino, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancerKazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, et al.
Pageof 26